IVT Enzyme Production for Higher-Yield, High-Quality mRNA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing clinical-grade enzymes for mRNA synthesis in therapeutic applications are inefficient and costly, lacking optimized plasmid constructs, protein production conditions, and purification protocols.
Innovation Solution
Optimized bacterial expression vectors with arabinose promoters and codon-optimized gene sequences for T7 RNA polymerase, Vaccinia Virus Capping Enzyme (VVCE) subunits, and Poly(A) polymerase, along with modified protein purification methods, including His tags and Tobacco Etch Virus protease sequences, are used to produce enzymes in-house, which are then applied in a sequential IVT process.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If commercially available enzymes are used for mRNA synthesis, then the process is simple, but the cost is high and the yield is low
Solution Approach 1:
The patent divides the mRNA production process into distinct modular components: optimized plasmid constructs for each enzyme (T7 RNA polymerase, Vaccinia virus capping enzyme, Poly(A) polymerase), standardized expression conditions, and purified protein products. This segmentation allows independent optimization of each enzyme's production while maintaining overall process simplicity.
Solution Approach 2:
The patent systematically optimizes multiple parameters including plasmid backbone selection, promoter strength, ribosome binding site sequences, codon usage, induction conditions (temperature, time, IPTG concentration), and purification parameters. These parameter changes collectively enhance enzyme production efficiency and mRNA yield while maintaining procedural simplicity.
2Ease of manufacture
If commercially available enzymes are used for mRNA synthesis, then the process is simple, but the cost is high
Solution Approach 1:
The patent enables laboratories to produce their own mRNA synthesis enzymes using standardized plasmid constructs and optimized bacterial expression systems. By self-producing T7 RNA polymerase, Vaccinia virus capping enzyme, and Poly(A) polymerase, researchers eliminate dependence on commercial suppliers and significantly reduce per-use enzyme costs while maintaining production simplicity through standardized protocols.
3Ease of manufacture
If non-optimized plasmid constructs are used for protein production, then the cloning is easier, but the protein yield and purity are low
Solution Approach 1:
The patent incorporates purification elements (His-tags, TEV protease sites) and optimized regulatory sequences (ribosome binding sites, codon optimization) into plasmid constructs during the cloning stage. This preliminary incorporation of purification and optimization features simplifies downstream processing while ensuring high protein purity and yield without complicating the initial cloning procedure.
4Speed
If non-optimized protein production conditions are used, then the production process is faster, but the enzyme activity and mRNA quality are low
Solution Approach 1:
The patent employs controlled induction protocols with specific time points and temperature shifts (e.g., overnight induction at 18°C followed by harvesting) to maximize protein solubility and activity. These periodic action patterns balance production speed with enzyme quality, allowing rapid yet reliable enzyme production for mRNA synthesis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in higher quality and yield of mRNA, as demonstrated by improved protein expression and transfection efficiency in transfected cells, surpassing commercially available enzymes.
Implementation Method 1
The insert further comprises an arabinose promoter sequence upstream of the polymerase sequence
Implementation Method 2
addition of nucleic acid sequences encoding His tags, wherein polymeric histidine is encoded in-frame with the protein sequence and placed at either the N or C terminus, and whereby proteins can be column purified after fermentation
Implementation Method 3
addition of a Tobacco Etch Virus protease sequence, whereby the His tag sequence can be proteolytically removed subsequent to protein purification
Implementation Method 4
the purified T7 RNA Polymerase is added to a reaction comprising linearized plasmid DNA encoding an mRNA transcript of interest. RNA is thereby transcribed from the linearized DNA via the action of the T7 RNA Polymerase
Implementation Method 5
A second reaction comprises the RNA transcript from the first reaction, S-adenosyl Methionine, and purified VVCE. The RNA transcript is thereby capped at the N-terminal to generate cap 0 mRNA
Implementation Method 6
A third reaction comprises capped mRNA from the VVCE reaction, purified poly(A) polymerase, and ATP, whereby a poly-adenylated tail is added to the 3′ end of the capped mRNA transcript
Data Source
AI summary
A method for the production of proteins used in the in vitro transcription (IVT) of messenger RNA (mRNA), wherein the proteins are evaluated for purity and efficacy by the efficiency with which mRNA synthetically derived therefrom, subsequently transfects cells and produces encoded proteins.